Gonadorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Synthetic GnRH — the same 10-amino-acid decapeptide your hypothalamus secretes. Gonadorelin is the GnRH molecule itself, provided exogenously. It acts one step up from HCG (which is at the testicles) and one step down from Kisspeptin (which is upstream of GnRH).
What does it do in my body?
- Binds GnRH receptors on pituitary gonadotrophs.
- Triggers LH + FSH release.
- Critical: must be dosed pulsatile, not constant. Constant GnRH exposure desensitizes the pituitary (this is actually how GnRH agonists work as chemical castration in prostate cancer — the opposite effect). For HPG restoration, gonadorelin must mimic the natural pulsatile rhythm — typically multiple small injections per day or via a pump.
How can it help me?
- Best fit: GnRH-to-pituitary signal insufficient; also used as a TRT-adjuvant replacement for HCG when HCG access is limited
- Where the science stands: Long-established pharmacology (gonadorelin = GnRH, textbook endocrinology); historical pulsatile-pump use in hypogonadotropic hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism)
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
- Generally well-tolerated.
- Constant (non-pulsatile) dosing produces paradoxical pituitary desensitization — the most common protocol error.
Regulatory status: Gonadorelin has a genuine clinical/diagnostic pedigree, not just a research-chem history. It has been used historically as a formal FDA diagnostic agent — the GnRH stimulation test, a real clinical procedure used to assess pituitary function. It is available through compounding pharmacies for HPG-axis use. It is banned by WADA for sport, in the same class as HCG.
For contrast, worth knowing: Triptorelin is a related decapeptide (a single D-Trp⁶ substitution vs. native GnRH) that functions as a GnRH superagonist with roughly 50–100× GnRH-receptor affinity and a long-acting profile — used for gonadal suppression (prostate cancer, endometriosis), the opposite clinical goal to gonadorelin’s restoration use here.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for Gonadorelin are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
- Pulsatile dosing is non-negotiable. Constant exposure desensitizes the receptor and produces the opposite effect.
- Community-typical TRT-adjuvant dose: 100–300 mcg SubQ, multiple times per day (often 2–3× daily).
- Half-life is short (minutes range) — this is why it must be pulsatile; a single daily bolus produces a brief spike and nothing else.
- Reconstitution: typical 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL = 100 mcg per 10 units on a U-100 insulin syringe.
What should I avoid combining — and what's synergistic?
Gonadorelin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Gonadorelin yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Wiki article (split 2026-07-16 from the retired HPGA-restoration cluster article, per-compound doctrine). Built from. Cross-links: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin. The broader “which lever matches your bloodwork” decision framework — the HPG-axis mechanism map, the decision algorithm, and the TRT-vs-restoration big picture — now lives in the Peptides 101 article HPGA Restoration: Choosing the Right Lever.
| Class | Synthetic GnRH — the same 10-amino-acid decapeptide the hypothalamus secretes |
| Mechanism (one line) | Binds GnRH receptors on pituitary gonadotrophs → triggers LH + FSH release; must be dosed pulsatile, not constant, or the pituitary desensitizes |
| Acts at | Pituitary (gonadotroph cells) — one step up from HCG (which acts at the testes), one step down from Kisspeptin (upstream of GnRH) |
| Route / frequency | SubQ injection, pulsatile dosing — typically multiple small injections per day |
| Best-fit use case | GnRH-to-pituitary signal insufficient; also used as a TRT-adjuvant replacement for HCG when HCG access is limited |
| Evidence base | Long-established pharmacology (gonadorelin = GnRH, textbook endocrinology); historical pulsatile-pump use in hypogonadotropic hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism) |
| Regulatory status | Real clinical pathway distinct from typical research-chem peptides — used historically as an FDA diagnostic agent (the GnRH stimulation test); available via compounding pharmacies |
| Alyve product | Not in Alyve’s current launch 15-SKU catalog — flagged as a roadmap candidate |
What it is
Synthetic GnRH — the same 10-amino-acid decapeptide your hypothalamus secretes. Gonadorelin is the GnRH molecule itself, provided exogenously. It acts one step up from HCG (which is at the testicles) and one step down from Kisspeptin (which is upstream of GnRH).
How it works
- Binds GnRH receptors on pituitary gonadotrophs.
- Triggers LH + FSH release.
- Critical: must be dosed pulsatile, not constant. Constant GnRH exposure desensitizes the pituitary (this is actually how GnRH agonists work as chemical castration in prostate cancer — the opposite effect). For HPG restoration, gonadorelin must mimic the natural pulsatile rhythm — typically multiple small injections per day or via a pump.
What the research shows
- Long-established pharmacology — gonadorelin = GnRH; the mechanism is textbook endocrinology.
- Clinical use historically in pulsatile-pump format for hypogonadotropic hypogonadism (Kallmann syndrome, idiopathic hypogonadotropic hypogonadism).
- More recent off-label use as a TRT-adjuvant (replacement for HCG when HCG access has been limited).
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
- Pulsatile dosing is non-negotiable. Constant exposure desensitizes the receptor and produces the opposite effect.
- Community-typical TRT-adjuvant dose: 100–300 mcg SubQ, multiple times per day (often 2–3× daily).
- Half-life is short (minutes range) — this is why it must be pulsatile; a single daily bolus produces a brief spike and nothing else.
- Reconstitution: typical 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL = 100 mcg per 10 units on a U-100 insulin syringe.
Side effects & management
- Generally well-tolerated.
- Constant (non-pulsatile) dosing produces paradoxical pituitary desensitization — the most common protocol error.
Regulatory status
Gonadorelin has a genuine clinical/diagnostic pedigree, not just a research-chem history. It has been used historically as a formal FDA diagnostic agent — the GnRH stimulation test, a real clinical procedure used to assess pituitary function. It is available through compounding pharmacies for HPG-axis use. It is banned by WADA for sport, in the same class as HCG.
For contrast, worth knowing: Triptorelin is a related decapeptide (a single D-Trp⁶ substitution vs. native GnRH) that functions as a GnRH superagonist with roughly 50–100× GnRH-receptor affinity and a long-acting profile — used for gonadal suppression (prostate cancer, endometriosis), the opposite clinical goal to gonadorelin’s restoration use here.
Technical & analytical reference (chemistry & QC)
Verified identity values (PubChem / CAS; identity confirmed, not from analytical capture).
| Field | Value |
|---|---|
| Formula | C55H75N17O13 |
| Avg MW | 1182.31 |
| CAS | 33515-09-2 |
| Sequence | pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 |
| PubChem CID | 638793 |
Native GnRH decapeptide; identity by HPLC-UV + LC-MS against the 1182.31 average mass.
Citation leads (PeptideBiologix; until confirmed): PeptideBiologix analytical page for Gonadorelin (raw capture ) — method/PK detail only; identity values above are from PubChem/CAS, not the capture.
Sources
- the 4-tool cascade-failure-point map, gonadorelin mechanism, pulsatile-dosing requirement.
triptorelin.md— analytical/method-detail raw captures ( pending).- Established endocrinology: HPG axis cascade, GnRH agonist vs. superagonist pharmacology.
Related: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin.
Sources & references
- the 4-tool cascade-failure-point map, gonadorelin mechanism, pulsatile-dosing requirement.
triptorelin.md— analytical/method-detail raw captures ( pending).- Established endocrinology: HPG axis cascade, GnRH agonist vs. superagonist pharmacology.
Related: Enclomiphene · HCG (Human Chorionic Gonadotropin) · Kisspeptin.